Premium
Method validation and determination of lisdexamfetamine and amphetamine in oral fluid, plasma and urine by LC–MS/MS
Author(s) -
Comiran Eloisa,
Barreto Fabiano,
Meneghini Leonardo Z.,
Carlos Graciela,
Fröehlich Pedro E.,
Limberger Renata Pereira
Publication year - 2017
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.3812
Subject(s) - chemistry , urine , chromatography , analyte , prodrug , stimulant , oral administration , liquid chromatography–mass spectrometry , pharmacology , mass spectrometry , biochemistry , medicine
Lisdexamfetamine (LDX) is a long‐acting prodrug stimulant indicated for the treatment of attention‐deficit/hyperactivity disorder and binge‐eating disorder symptoms. In vivo hydrolysis of LDX amide bond releases the therapeutically active d ‐amphetamine ( d ‐AMPH). Since toxicological tests in biological samples can detect AMPH from the use of some legal medications, efficient methods are needed in order to correctly interpret the results. The aim of this study was to develop and validate an LC–MS/MS method for the simultaneous quantification of LDX and its main biotransformation product AMPH in human oral fluid, plasma and urine. Calibration curve range for both analytes was 1–128 ng/mL in oral fluid and plasma and 4–256 ng/mL in urine, being the lowest concentration the limit of quantification. Accuracy of the determined values of the target analytes for the five control levels ranged from 94.8 to 111.7% for oral fluid, from 91.3 to 100.2% for plasma and from 94.8 to 109.8% for urine. Imprecision for the five control levels did not exceeded 12.8% for oral fluid, 16.2% for plasma and 17.1% for urine. The method developed for the three matrices was validated and was also successfully applied to assess real samples, showing for the first time the detection of LDX in oral fluid.